Edition:
India

Blueprint Medicines Corp (BPMC.OQ)

BPMC.OQ on NASDAQ Stock Exchange Global Select Market

81.44USD
16 Feb 2018
Change (% chg)

$-1.11 (-1.34%)
Prev Close
$82.55
Open
$81.94
Day's High
$84.03
Day's Low
$81.23
Volume
76,248
Avg. Vol
168,200
52-wk High
$92.00
52-wk Low
$32.98

Chart for

About

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug... (more)

Overall

Beta: --
Market Cap(Mil.): $2,592.25
Shares Outstanding(Mil.): 39.12
Dividend: --
Yield (%): --

Financials

BRIEF-Blueprint Medicines Prices Public Offering Of 3.70 Mln Shares At $81.00/Share

* BLUEPRINT MEDICINES ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK

13 Dec 2017

BRIEF-Blueprint Medicines Announces Proposed Public Offering Of Shares Of Common Stock

* BLUEPRINT MEDICINES ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK

12 Dec 2017

BRIEF-Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285

* Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285 in patients with advanced gastrointestinal stromal tumors showing strengthened clinical activity across spectrum of kit and pdgfrα genotypes

10 Nov 2017

BRIEF-Thermo Fisher enters agreement with Blueprint Medicines​

* Thermo Fisher Scientific Inc - ‍ expanded development of Oncomine Dx Target Test by entering into an agreement with Blueprint Medicines Corporation​

31 Oct 2017

BRIEF-Blueprint Medicines Q3 loss per share $0.96

* Blueprint Medicines reports third quarter 2017 financial results

31 Oct 2017

Competitors

Earnings vs. Estimates